Latest news with #GPP
Yahoo
21 hours ago
- Business
- Yahoo
LEO Pharma secures rights to Boehringer's Spevigo for $105m
Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim's psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening its portfolio ahead of a possible public listing in 2026. The transaction will see LEO gain the exclusive global licence for Spevigo, taking control of commercialisation and development rights. The full terms of the deal were not disclosed as both companies are privately owned, but LEO confirmed it is in line for milestone payments and royalties. The deal is expected to close in the second half of 2025. Spevigo is approved in the US, Japan, China and most European countries to treat generalised pustular psoriasis (GPP) flares, a rare but severe dermatological disease that can be fatal. It has also been approved in expanded indications in GPP in certain territories. LEO's new asset is a monoclonal antibody that blocks the activation of the interleukin-36 (IL-36) receptor - a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases. Indeed, GPP may not be the ceiling for Spevigo – LEO said there is an 'opportunity to investigate the potential of Spevigo in additional skin conditions with high unmet medical need in which IL-36 is implicated'. LEO calls Spevigo 'the flagship dermatology product' of Boehringer Ingelheim, though the drug's sales have not been publicly disclosed. Comparing sales from other drugs is tricky because Spevigo is the only US Food and Drug Administration (FDA)-approved treatment specifically for GPP. Boehringer Ingelheim's head of human pharma Shashank Deshpande said: 'Spevigo holds a significant promise, and ensuring it reaches its full potential requires continued focus and expertise in medical dermatology. With over six decades of singular dedication to this field, LEO Pharma is exceptionally well-positioned to build on the strong foundation we've laid.' Adding Spevigo to its portfolio represents a strengthening of assets for dermatology specialist LEO. The Danish drugmaker has been building its pipeline amid reports it is planning an initial public offering (IPO) next year. Christophe Bourdon, who was appointed CEO in 2022 and tasked with turning the fortunes of the company around, has made no secret of public listing plans. In an interview with Bloomberg yesterday [14 July], Bourdon said market conditions and shareholders' wishes will decide the best timing for an IPO. The deal with Boehringer Ingelheim marks the second time LEO has signed a licensing agreement with a big pharma company in 2025. In January, Gilead Sciences offered a potential $1.7bn for LEO's preclinical STAT6 research programmes, which the dermatology company agreed to. As part of the deal, LEO received $250m in an upfront payment, boosting its cash on hand. "LEO Pharma secures rights to Boehringer's Spevigo for $105m" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Boehringer Ingelheim and LEO Pharma Enter Partnership to Commercialize and Further Develop SPEVIGO® (spesolimab)
Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma's six decades of dermatology expertise and Boehringer's global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will closely cooperate to ensure a smooth transition of all operations INGELHEIM, Germany & BALLERUP, Denmark, July 14, 2025--(BUSINESS WIRE)--GLOBAL RELEASE - NOT INTENDED FOR UK MEDIA Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and transfer agreement to commercialize and advance the development of SPEVIGO® (spesolimab). SPEVIGO® is an innovative, humanized, and selective monoclonal antibody that targets and blocks the activation of the interleukin-36 (IL-36) receptor - a key signaling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases, including generalized pustular psoriasis (GPP).123 This partnership extends beyond GPP, with an opportunity to investigate the potential of spesolimab in additional skin conditions with high unmet medical need in which IL-36 is implicated. Under the terms of the agreement, LEO Pharma will be responsible for commercialization and further development of SPEVIGO® leveraging its global commercial platform within medical dermatology to raise disease awareness and secure access for patients with GPP. The addition of Boehringer Ingelheim's flagship dermatology product, SPEVIGO®, for the treatment of GPP, complements LEO Pharma's existing strategic dermatology portfolio and reinforces its long-standing commitment to delivering transformational medicines to patients. "We are immensely proud of what SPEVIGO® represents for people living with GPP and bringing innovation to this community of patients has been a powerful reflection of our purpose to transform lives," said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. "SPEVIGO® holds a significant promise, and ensuring it reaches its full potential requires continued focus, and expertise in medical dermatology. With over six decades of singular dedication to this field, LEO Pharma is exceptionally well-positioned to build on the strong foundation we've laid. We remain profoundly grateful to the patients, caregivers, and healthcare professionals who have walked this journey with us." "Skin diseases can profoundly impact people's lives - and at LEO Pharma, we are here to change that," said Christophe Bourdon, CEO of LEO Pharma. "Partnering to bring SPEVIGO® to more patients is more than a strategic step - it means the opportunity to help people living with GPP by addressing a disease with limited treatment options and aiming to improve their quality of life. We are inspired by Boehringer Ingelheim's pioneering efforts and thrilled to build on that foundation. Together, we have a powerful opportunity to expand access to innovative care and deliver meaningful progress for patients who have long been underserved." GPP is a rare, heterogeneous, and potentially life-threatening skin disease. It is characterized by the accumulation of neutrophils (a type of white blood cell) in the skin, leading to painful, sterile pustules across the body. The disease course varies, with some patients experiencing relapsing episodes with recurrent flares - often accompanied by fever, malaise, fatigue, and a risk of organ failure - while others endure persistent disease with intermittent flares.7891011 SPEVIGO® is available in more than 40 countries including the U.S., Japan, China, and most European countries to treat GPP flares in adults.4 It is the first approved treatment for GPP flares that specifically targets the IL-36 pathway and that has been evaluated in a statistically powered, randomized, placebo-controlled trial.5 Additionally, SPEVIGO® has also been approved for expanded indications in generalized pustular psoriasis in the EU, U.S. and China.6 SPEVIGO® is also under investigation for the treatment of other IL-36 mediated skin diseases. The transaction is anticipated to close in the second half of 2025, subject to merger control clearance, with Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties. July, 2025 About Spevigo SPEVIGO® is a novel, humanized, selective antibody that specifically blocks the activation of the IL-36R, a signalling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP. It is the first targeted therapy for the treatment of GPP and has been evaluated in the largest clinical program specifically for the treatment of patients with GPP.123 About generalized pustular psoriasis (GPP) GPP is a chronic, heterogenous, neutrophilic inflammatory disease associated with skin and systemic symptoms that is distinct from plaque psoriasis. GPP is recognized as a separate clinical entity from other forms of psoriasis, with the IL-36 pathway being a key driver of GPP and triggering response to treatment.78 GPP can become life-threatening (mortality rates ranging from 2% to 16%) due to severe complications, such as multisystem organ failure and sepsis requiring urgent hospital care; many GPP patients also suffer from various comorbidities, which contribute to the ongoing burden for the patient and healthcare systems.89 GPP symptoms appear unpredictable and present on a continuum, which greatly impacts a patient's quality of life, and may cause fear and anxiety over the disease course, as well as long-term impacts on quality of life related to work/school, emotional health, social activities, and finances.81011 About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serve close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit 1 Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402:1541–1551.2 Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11:e043666.3 Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385:2431–2440.4 Record on file.5 Boehringer Ingelheim. Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial. 2023. (Accessed 22 July 2024).6 Boehringer Ingelheim. European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis. 2024. (Accessed 29 June 2025).7 Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:13–19.8 Prinz JC, Choon SE, Griffiths CEM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review. J Eur Acad Dermatol Venereol. 2023;37:256–273.9 Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:21–29.10 Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907–919.11 Reisner DV, Johnsson FD, Kotowsky N, et al. Impact of generalized pustular psoriasis from the perspective of people living with the condition: Results of an online survey. Am J Clin Dermatol. 2022;23:65–71. View source version on Contacts Boehringer Ingelheim Tereza Urbankova, Senior Media Relations ManagerE-Mail: press@ Phone Number: +49 (6132) 77-184817LEO Pharma Jeppe Ilkjær, MediaE-Mail: jeilk@ Phone Number: +45 3050 2014Christian Soerup Ryom, InvestorsE-Mail: chsoe@ Phone Number: +45 3089 9083 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 days ago
- Business
- Business Wire
Boehringer Ingelheim and LEO Pharma Enter Partnership to Commercialize and Further Develop SPEVIGO ® (spesolimab)
INGELHEIM, Germany & BALLERUP, Denmark--(BUSINESS WIRE)-- GLOBAL RELEASE - NOT INTENDED FOR UK MEDIA Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and transfer agreement to commercialize and advance the development of SPEVIGO ® (spesolimab). SPEVIGO ® is an innovative, humanized, and selective monoclonal antibody that targets and blocks the activation of the interleukin-36 (IL-36) receptor - a key signaling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases, including generalized pustular psoriasis (GPP). 123 This partnership extends beyond GPP, with an opportunity to investigate the potential of spesolimab in additional skin conditions with high unmet medical need in which IL-36 is implicated. Under the terms of the agreement, LEO Pharma will be responsible for commercialization and further development of SPEVIGO® leveraging its global commercial platform within medical dermatology to raise disease awareness and secure access for patients with GPP. The addition of Boehringer Ingelheim's flagship dermatology product, SPEVIGO ®, for the treatment of GPP, complements LEO Pharma's existing strategic dermatology portfolio and reinforces its long-standing commitment to delivering transformational medicines to patients. 'We are immensely proud of what SPEVIGO ® represents for people living with GPP and bringing innovation to this community of patients has been a powerful reflection of our purpose to transform lives,' said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. 'SPEVIGO ® holds a significant promise, and ensuring it reaches its full potential requires continued focus, and expertise in medical dermatology. With over six decades of singular dedication to this field, LEO Pharma is exceptionally well-positioned to build on the strong foundation we've laid. We remain profoundly grateful to the patients, caregivers, and healthcare professionals who have walked this journey with us.' 'Skin diseases can profoundly impact people's lives - and at LEO Pharma, we are here to change that,' said Christophe Bourdon, CEO of LEO Pharma. 'Partnering to bring SPEVIGO® to more patients is more than a strategic step - it means the opportunity to help people living with GPP by addressing a disease with limited treatment options and aiming to improve their quality of life. We are inspired by Boehringer Ingelheim's pioneering efforts and thrilled to build on that foundation. Together, we have a powerful opportunity to expand access to innovative care and deliver meaningful progress for patients who have long been underserved.' GPP is a rare, heterogeneous, and potentially life-threatening skin disease. It is characterized by the accumulation of neutrophils (a type of white blood cell) in the skin, leading to painful, sterile pustules across the body. The disease course varies, with some patients experiencing relapsing episodes with recurrent flares - often accompanied by fever, malaise, fatigue, and a risk of organ failure - while others endure persistent disease with intermittent flares. 7891011 SPEVIGO ® is available in more than 40 countries including the U.S., Japan, China, and most European countries to treat GPP flares in adults. 4 It is the first approved treatment for GPP flares that specifically targets the IL-36 pathway and that has been evaluated in a statistically powered, randomized, placebo-controlled trial. 5 Additionally, SPEVIGO® has also been approved for expanded indications in generalized pustular psoriasis in the EU, U.S. and China. 6 SPEVIGO ® is also under investigation for the treatment of other IL-36 mediated skin diseases. The transaction is anticipated to close in the second half of 2025, subject to merger control clearance, with Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties. July, 2025 About Spevigo SPEVIGO® is a novel, humanized, selective antibody that specifically blocks the activation of the IL-36R, a signalling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP. It is the first targeted therapy for the treatment of GPP and has been evaluated in the largest clinical program specifically for the treatment of patients with GPP. 123 About generalized pustular psoriasis (GPP) GPP is a chronic, heterogenous, neutrophilic inflammatory disease associated with skin and systemic symptoms that is distinct from plaque psoriasis. GPP is recognized as a separate clinical entity from other forms of psoriasis, with the IL-36 pathway being a key driver of GPP and triggering response to treatment. 78 GPP can become life-threatening (mortality rates ranging from 2% to 16%) due to severe complications, such as multisystem organ failure and sepsis requiring urgent hospital care; many GPP patients also suffer from various comorbidities, which contribute to the ongoing burden for the patient and healthcare systems. 89 GPP symptoms appear unpredictable and present on a continuum, which greatly impacts a patient's quality of life, and may cause fear and anxiety over the disease course, as well as long-term impacts on quality of life related to work/school, emotional health, social activities, and finances. 81011 About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serve close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit 1 Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402:1541–1551. 2 Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11:e043666. 3 Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385:2431–2440. 4 Record on file. 5 Boehringer Ingelheim. Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial. 2023. (Accessed 22 July 2024). 6 Boehringer Ingelheim. European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis. 2024. (Accessed 29 June 2025). 7 Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:13–19. 8 Prinz JC, Choon SE, Griffiths CEM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review. J Eur Acad Dermatol Venereol. 2023;37:256–273. 9 Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:21–29. 10 Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907–919. 11 Reisner DV, Johnsson FD, Kotowsky N, et al. Impact of generalized pustular psoriasis from the perspective of people living with the condition: Results of an online survey. Am J Clin Dermatol. 2022;23:65–71.
GMA Network
03-07-2025
- General
- GMA Network
DepEd expands school garden, farm school programs to support nutrition, agri-education
The Department of Education (DepEd) has expanded its Gulayan sa Paaralan Program (GPP) to cover 44,965 schools nationwide this school year — a 50.6% increase from 2022–2023. The GPP plays a pivotal role in supporting DepEd's year-round School-Based Feeding Program (SBFP) by supplying nutritious, locally grown produce while enriching nutrition education among learners — a model that has gained traction especially in geographically isolated and disadvantaged areas. Funded through local school resources and the SBFP, the GPP empowers schools to grow fresh, organic vegetables that supplement student meals. These gardens also serve as outdoor classrooms where students learn about agriculture, sustainability, and food security—particularly vital in rural and last-mile communities. 'Kapag natuto ang mga bata kung saan nanggagaling ang pagkain nila at paano ito pinapalaki, mas naeengganyo silang kumain nang masustansya,' said Education Secretary Juan Edgardo 'Sonny' Angara in a statement Thursday. (When children understand where their food comes from and how it's grown, they are more encouraged to eat healthy.) 'Hindi lang ito tungkol sa gulay. Disiplina, pagtutulungan, at malasakit sa kalikasan at kapwa ang tinuturo natin dito,' he added. (This isn't just about vegetables. We're teaching discipline, cooperation, and caring for the environment as well as others.) As of 2025, 94% of public schools are implementing garden-based learning interventions. DepEd has also significantly increased GPP funding, from ?10 million in 2021 to ?20 million in 2024, with a projected ?21.8 million budget for 2025 — reflecting the Department's sustained commitment to nutrition and holistic learning. Complementing the Gulayan sa Paaralan is DepEd's continued expansion of Farm Schools, an initiative originally championed by the late Senator Edgardo J. Angara and institutionalized through Republic Act No. 10618, or the Rural Farm Schools Act. There are currently 152 farm schools operating across four regions, providing hands-on training in agriculture, agribusiness, and entrepreneurial skills — particularly for learners in rural areas. 'Kailangan nating palakasin ang suporta sa mga farm school dahil mahalagang bahagi ito ng food security at pag-unlad ng kabuhayan sa kanayunan,' Secretary Angara emphasized. (We need to strengthen support for farm schools because they are vital to food security and rural economic development.) Angara reiterated the need for increased investment in farm schools to equip students with practical skills aligned with national goals on agriculture, sustainability, and inclusive growth. —Sherylin Untalan/RF, GMA Integrated News
Barnama
26-06-2025
- Business
- Barnama
Bureaucratic Reform: Communications Ministry Slashes Red Tape For Foreign Film Approvals
GENERAL PUTRAJAYA, June 26 (Bernama) -- The Ministry of Communications has successfully reduced the script approval processing time for international film production companies from 30 days to just seven, marking a significant step in bureaucratic reform, said Communications Minister Datuk Fahmi Fadzil. Speaking at his weekly press conference today, Fahmi, who is also MADANI Government spokesperson, said the achievement is particularly noteworthy for the National Film Development Corporation Malaysia (FINAS), as it addresses a critical need for thorough script reviews for foreign film shoots in Malaysia. 'Several other agencies under the Ministry of Communications have also undergone reform to reduce bureaucratic red tape. For instance, PUSPAL (Central Agency for Application of Filming and Performance by Foreign Artistes) previously took a much longer time to process applications. 'However, following the launch of GPP (PUSPAL Guidelines) 6.0 last April, many processes have been streamlined, especially in organising concerts and managing film productions involving foreign artistes and companies,' he said. He also stated that the ministry is committed to further intensifying reform efforts across its agencies and statutory bodies, including the Malaysian Communications and Multimedia Commission (MCMC). The Communications Ministry is among the top three ministries recognised for successfully implementing bureaucratic reform and was recently awarded a special commendation for its achievements. Chief Secretary to the Government, Tan Sri Shamsul Azri Abu Bakar, even noted that the ministry's efforts have improved the efficiency of foreign script approvals, reducing processing time from 30 days to seven, which resulted in regulatory cost savings of up to RM2.4 million per production, hence strengthening Malaysia's competitiveness as a preferred international filming destination. The ministry's secretary-general, Datuk Mohamad Fauzi Md Isa, received the special certificate of appreciation from Shamsul Azri at a ceremony held in Putrajaya on Tuesday. The Ministry of Housing and Local Government (KPKT) and the Ministry of Investment, Trade and Industry (MITI) were also recognised for their achievements in cutting red tape.
